BioCentury | Nov 3, 2014
Finance

Shooting F-stars

F-star Alpha Ltd. 's deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller...
BioCentury | Aug 4, 2014
Finance

Voucher leapfrog

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) are hoping to use a newly acquired Priority Review voucher to jump ahead of Amgen Inc. (NASDAQ:AMGN) in the race to be first to market with a...
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
BC Week In Review | Nov 10, 2008
Clinical News

Coniel benidipine regulatory update

Kyowa Hakko Kirin said China's State Food and Drug Administration approved Coniel to treat angina pectoris. The company has marketed the oral calcium antagonist in China to treat hypertension since December 2004. Kyowa Hakko Kirin...
BC Week In Review | Oct 29, 2007
Company News

Kirin Holdings Co. Ltd., Kyowa Hakko Kogyo Co. Ltd. deal

Kyowa Hakko and Kirin's Kirin Pharma Co. Ltd. subsidiary will merge to create Kyowa Hakko Kirin Co. Ltd. Kirin Holdings will acquire 112 million shares (27.95%) of Kyowa Hakko for ¥1,500 per share, or about...
Items per page:
1 - 5 of 5